Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
12 Dec 2019
Historique:
received: 21 11 2019
revised: 03 12 2019
accepted: 06 12 2019
entrez: 18 12 2019
pubmed: 18 12 2019
medline: 1 5 2020
Statut: epublish

Résumé

Preclinical drug development for human chronic lymphocytic leukemia (CLL) requires robust xenograft models recapitulating the entire spectrum of the disease, including all prognostic subgroups. Current CLL xenograft models are hampered by inefficient engraftment of good prognostic CLLs, overgrowth with co-transplanted T cells, and the need for allogeneic humanization or irradiation. Therefore, we aimed to establish an effective and reproducible xenograft protocol which allows engraftment of all CLL subtypes without the need of humanization or irradiation. Unmanipulated NOD.Cg-

Identifiants

pubmed: 31842407
pii: ijms20246277
doi: 10.3390/ijms20246277
pmc: PMC6940872
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Krebshilfe
ID : 111025
Organisme : Deutsche Krebshilfe
ID : 70112614
Organisme : Deutsche Forschungsgemeinschaft
ID : DI 1664/1-1
Organisme : Deutsche Forschungsgemeinschaft
ID : DI 1664/2-2
Organisme : Deutsche Forschungsgemeinschaft
ID : DI 1664/3-1
Organisme : José Carreras Leukämie-Stiftung
ID : DJCLS F15/3

Références

N Engl J Med. 2005 Feb 24;352(8):804-15
pubmed: 15728813
N Engl J Med. 1995 Oct 19;333(16):1052-7
pubmed: 7675049
Med Hypotheses. 2006;66(3):577-9
pubmed: 16223567
Leukemia. 2013 Dec;27(12):2311-21
pubmed: 23619564
Stem Cell Res. 2016 Nov;17(3):646-653
pubmed: 27865162
Br J Haematol. 1989 Mar;71(3):343-50
pubmed: 2930721
Nat Cell Biol. 2017 Aug;19(8):891-903
pubmed: 28714970
Nature. 2011 Jun 05;475(7354):101-5
pubmed: 21642962
JCI Insight. 2016 Apr 7;1(4):null
pubmed: 27158669
Hum Pathol. 2011 May;42(5):719-26
pubmed: 21292300
Cell Stem Cell. 2014 Aug 7;15(2):227-38
pubmed: 25017720
Blood Adv. 2016 Nov 22;1(1):47-61
pubmed: 29296695
Blood. 2013 Feb 28;121(9):1612-21
pubmed: 23247726
Hematol Oncol Clin North Am. 2013 Apr;27(2):207-35
pubmed: 23561470
Leukemia. 1997 May;11(5):687-93
pubmed: 9180293
Blood. 1999 Sep 15;94(6):1840-7
pubmed: 10477712
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60
pubmed: 12011454
J Clin Oncol. 2013 Jan 1;31(1):88-94
pubmed: 23045577
Clin Exp Immunol. 2011 Nov;166(2):154-63
pubmed: 21985361
Blood. 2010 Feb 25;115(8):1605-9
pubmed: 20018917
J Clin Invest. 2018 Jan 2;128(1):427-445
pubmed: 29227286
Br J Haematol. 1998 Nov;103(2):335-42
pubmed: 9827902
Curr Pathobiol Rep. 2016 Dec;4(4):221-230
pubmed: 28462013
Blood. 2011 May 19;117(20):5463-72
pubmed: 21385850
Cancer Res. 2007 Sep 15;67(18):8653-61
pubmed: 17875705
Blood. 2012 Aug 9;120(6):1175-84
pubmed: 22715122
Blood. 2002 Nov 1;100(9):3175-82
pubmed: 12384415
Leuk Lymphoma. 2004 Dec;45(12):2365-72
pubmed: 15621749
N Engl J Med. 2013 Jul 4;369(1):32-42
pubmed: 23782158
Blood. 2017 Feb 23;129(8):959-969
pubmed: 28077418
Stem Cell Reports. 2015 Feb 10;4(2):171-80
pubmed: 25601207
Blood. 2003 Jun 15;101(12):4944-51
pubmed: 12595313
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Blood. 2000 Oct 15;96(8):2655-63
pubmed: 11023495
Clin Adv Hematol Oncol. 2013 Aug;11 Suppl 9(8):6-10
pubmed: 25856367
Blood. 1997 Mar 15;89(6):2210-8
pubmed: 9058746
Leukemia. 2013 Mar;27(3):534-40
pubmed: 23041721
Cancer Cell. 2010 Jan 19;17(1):28-40
pubmed: 20060366
Dis Model Mech. 2015 Nov;8(11):1401-12
pubmed: 26398941
Hematology Am Soc Hematol Educ Program. 2011;2011:96-103
pubmed: 22160019
Clin Cancer Res. 2017 Jun 1;23(11):2831-2841
pubmed: 27903679
Semin Oncol. 2006 Apr;33(2):150-6
pubmed: 16616061
N Engl J Med. 2004 Aug 26;351(9):893-901
pubmed: 15329427
Eur J Haematol. 2011 Jul;87(1):10-9
pubmed: 21692849
Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16600-5
pubmed: 15545599
Cell. 2013 Feb 14;152(4):714-26
pubmed: 23415222
Cancer Res. 1999 Dec 1;59(23):5968-74
pubmed: 10606243

Auteurs

Sarah Decker (S)

Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Anabel Zwick (A)

Institute of Virology, Saarland University, 66421 Homburg/Saar, Germany.

Shifa Khaja Saleem (S)

Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Sandra Kissel (S)

Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Andres Rettig (A)

Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Konrad Aumann (K)

Department of Pathology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.

Christine Dierks (C)

Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
BIOSS Centre for Biological Signaling Studies, University of Freiburg, 79106 Freiburg, Germany.
Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital, 8091 Zurich, Switzerland.
Division of Hematology, University Hospital Zürich and University of Zurich, 8091 Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH